Resumo da palestra NurAiD II na recuperação do AVC: Fundamentos científicos e experiência clínica, pelo Dr. Carlos de la Cruz Cosme no Curso de Atualização em Doença Vascular Cerebral, Faculdade de Medicina da Universidade do Porto, 21 de junho de 2017, publicado no INTERNATIONAL JOURNAL OF CLINICAL NEUROSCIENCES AND MENTAL HEALTH.
Hossein Pakdaman (a), Ali Amini Harandi (a), Hamidreza Hatamian (c), Mojgan Tabatabae (b), Hosein Delavar Kasmaei (a), Amirhossein Ghassemi (d), Koroush Gharagozli a Farzad Ashrafi a Pardis Emami Naeini (e), Mehrnaz Tavakolian (a), Darush Shahin (a). (a) - Department of Neurology, Shahid Beheshti University of Medical Sciences, and (b) - Social Security, Tehran , (c) - Department of Neurology, Rasht University of Medical Sciences, Rasht (d) - Social Security, Kerman , and e School of Medicine, Isfahan University of Medical Sciences, Isfahan , Iran. Dement Geriatr Cogn Disord Extra 2015;5:96–106 Abstract Background: MLC601 is a possible modulator of amyloid precursor protein processing, and in a clinical trial study MLC601 showed some effectiveness in cognitive function in Alzheimer’s disease (AD) patients. We aimed to evaluate the effectiveness and safety of MLC601 in the treatment of mild to moderate AD as compared to 3 approved cholinesterase inhibitors (ChEIs) including donepezil, rivastigmine and galantamine. Methods: In a multicenter, nonblinded, randomized controlled trial, 264 volunteers with AD were randomly divided into 4 groups of 66; groups 1, 2, 3 and 4 received donepezil, rivastigmine, MLC601 and galantamine, respectively. Subjects underwent a clinical diagnostic interview and a cognitive/functional battery including the Mini-Mental State Examination (MMSE) and Alzheimer’s Disease Assessment Scale – Cognitive subscale (ADAS-Cog). Patients were visited every 4 months, and the score of cognition was recorded by the neurologists. Results: There were no significant differences in age, sex, marital status and baseline score of cognition among the 4 groups. In total, 39 patients (14.7%) left the study. Trend of cognition changes based on the modifications over the time for MMSE and ADAS-cog scores did not differ significantly among groups (p = 0.92 for MMSE and p = 0.87 for ADAS-Cog). Conclusion: MLC601 showed a promising safety profile and also efficacy compared to 3 FDA-approved ChEIs.